Danish drugmaker Novo Nordisk (NVO) is investing $1.20 billion U.S. in a new facility that will produce medications to treat ...

Part of the joy of the season may be gone — or feel different — for people who are taking popular weight-loss drugs and can't ...

Here are five things to know about GLP-1s and increased healthcare utilization: 1. According to the report, an uptick in GLP-1 use is facilitating a range of "crucial preventive care," including pap ...

The Danish Medicines Agency said it would ask European authorities to review two new studies that point to a link between ...

New weight-loss medications are reshaping U.S. healthcare by increasing diagnoses of obesity-related conditions and encouraging patients' engagement with health services. These drugs, including Wegovy ...

The Danish Medicines Agency had been watching reports of a rare eye disease in patients who took Novo’s GLP-1 drug but until ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Novo Nordisk (NVO) is making headlines with its inventive investment of $1.2 billion aimed at building a new production ...

Novo Nordisk’s takeover of Catalent and the Danish firm’s push to launch a new generation of drugs could boost the importance ...

Study confirms link between Ozempic's active ingredient and low risk of vision loss. Ophthalmology organizations recommend continued use.

Danish studies have found a potential link between the diabetes drug Ozempic and a rare eye condition called non-arteritic ...

The dip was slight but was the first such decline in a decade. Separately, a study links Ozempic with an increased risk of a rare form of vision loss, and another study links seed oils with an ...